Prostate Specific Antigen Kinetics in the Management of Prostate Cancer

Journal of Urology

Volumn 179, Issue 3, 2008, Pages 821-826

  Sengupta, Shomik ^a   Amling, Christopher ^b   D'Amico, Anthony V ^c   Blute, Michael L ^a  

^a MAYO CLINIC   (United States)

^b Alabama   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

prostate specific antigen; prostatectomy; prostatic neoplasms; radiotherapy; survival

Indexed keywords

DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; DATA BASE; DECISION MAKING; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MEDICAL INFORMATION; MEDLINE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT FAILURE;

HUMANS; KINETICS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 39149120824     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.10.023     Document Type: Review

References (50)

1. Carter H.B., Pearson J.D., Metter E.J., Brant L.J., Chan D.W., Andres R., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215
2. Schmid H.P., McNeal J.E., and Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71 (1993) 2031
3. Sengupta S., Slezak J.M., Blute M.L., and Bergstralh E.J. Simple graphic method for estimation of prostate-specific antigen doubling time. Urology 67 (2006) 408
4. Ross P.L., Mahmud S., Stephenson A.J., Souhami L., Tanguay S., and Aprikian A.G. Variations in PSA doubling time in patients with prostate cancer on "watchful waiting": value of short-term PSADT determinations. Urology 64 (2004) 323
5. Hardie C., Parker C., Norman A., Eeles R., Horwich A., Huddart R., et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 95 (2005) 956
6. Stephenson A.J., Aprikian A.G., Souhami L., Behlouli H., Jacobson A.I., Begin L.R., et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 59 (2002) 652
7. Choo R., DeBoer G., Klotz L., Danjoux C., Morton G.C., Rakovitch E., et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys 50 (2001) 615
8. Gerber G.S., Gornik H.L., Goldfischer E.R., Chodak G.W., and Rukstalis D.B. Evaluation of changes in prostate specific antigen in clinically localized prostate cancer managed without initial therapy. J Urol 159 (1998) 1243
9. McLaren D.B., McKenzie M., Duncan G., and Pickles T. Watchful waiting or watchful progression?. Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer 82 (1998) 342
10. el-Geneidy M., Garzotto M., Panagiotou I., Hsieh Y.C., Mori M., Peters L., et al. Delayed therapy with curative intent in a contemporary prostate cancer watchful-waiting cohort. BJU Int 93 (2004) 510
11. Carter C.A., Donahue T., Sun L., Wu H., McLeod D.G., Amling C., et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol 21 (2003) 4001
12. Fall K., Garmo H., Andren O., Bill-Axelson A., Adolfsson J., Adami H.O., et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 99 (2007) 526
13. Carter H.B., Ferrucci L., Kettermann A., Landis P., Wright E.J., Epstein J.I., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98 (2006) 1521
14. D'Amico A.V., Chen M.H., Roehl K.A., and Catalona W.J. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 (2004) 125
15. Sengupta S., Myers R.P., Slezak J.M., Bergstralh E.J., Zincke H., and Blute M.L. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191
16. Patel D.A., Presti Jr. J.C., McNeal J.E., Gill H., Brooks J.D., and King C.R. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol 23 (2005) 6157
17. Stephenson A.J., Kattan M.W., Eastham J.A., Dotan Z.A., Bianco Jr. F.J., Lilja H., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3973
18. Tollefson M.K., Slezak J.M., Leibovich B.C., Zincke H., and Blute M.L. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy. Mayo Clin Proc 82 (2007) 422
19. Lin D.D., Schultz D., Renshaw A.A., Rubin M.A., Richie J.P., and D'Amico A.V. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology 65 (2005) 528
20. Dotan Z.A., Bianco Jr. F.J., Rabbani F., Eastham J.A., Fearn P., Scher H.I., et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 23 (2005) 1962
21. Lee A.K., and D'Amico A.V. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol 23 (2005) 8192
22. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
23. Roberts S.G., Blute M.L., Bergstralh E.J., Slezak J.M., and Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76 (2001) 576
24. Partin A.W., Pearson J.D., Landis P.K., Carter H.B., Pound C.R., Clemens J.Q., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43 (1994) 649
25. Trapasso J.G., deKernion J.B., Smith R.B., and Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152 (1994) 1821
26. Zhou P., Chen M.H., McLeod D., Carroll P.R., Moul J.W., and D'Amico A.V. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992
27. D'Amico A.V., Moul J.W., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (2003) 1376
28. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 25 (2007) 1765
29. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., and Blute M.L. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172 (2004) 2244
30. Moul J.W., Wu H., Sun L., McLeod D.G., Amling C., Donahue T., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141
31. Sengupta S., Blute M.L., Bagniewski S.M., Myers R.P., Bergstralh E.J., Leibovich B.C., et al. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. J Urol 175 (2006) 1684
32. Hanks G.E., Hanlon A.L., Lee W.R., Slivjak A., and Schultheiss T.E. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34 (1996) 549
33. D'Amico A.V., Renshaw A.A., Sussman B., and Chen M.H. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294 (2005) 440
34. Eggener S.E., Roehl K.A., Yossepowitch O., and Catalona W.J. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol 176 (2006) 1399
35. D'Amico A.V., Loffredo M., Renshaw A.A., Loffredo B., and Chen M.H. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol 24 (2006) 4190
36. Bates A.T., Pickles T., and Paltiel C. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys 62 (2005) 148
37. Buyyounouski M.K., Hanlon A.L., Horwitz E.M., Uzzo R.G., and Pollack A. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys 61 (2005) 1291
38. Cheung R., Tucker S.L., and Kuban D.A. First-year PSA kinetics and minima after prostate cancer radiotherapy are predictive of overall survival. Int J Radiat Oncol Biol Phys 66 (2006) 20
39. Ciezki J.P., Reddy C.A., Garcia J., Angermeier K., Ulchaker J., Mahadevan A., et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 64 (2006) 512
40. Sartor C.I., Strawderman M.H., Lin X.H., Kish K.E., McLaughlin P.W., and Sandler H.M. Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. Int J Radiat Oncol Biol Phys 38 (1997) 941
41. Spiess P.E., Lee A.K., Leibovici D., Wang X., Do K.A., and Pisters L.L. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 107 (2006) 275
42. Zagars G.K., and Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44 (1997) 213
43. Lee A.K., Levy L.B., Cheung R., and Kuban D. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63 (2005) 456
44. Zelefsky M.J., Ben-Porat L., Scher H.I., Chan H.M., Fearn P.A., Fuks Z.Y., et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 23 (2005) 826
45. Stock R.G., Cesaretti J.A., and Stone N.N. Disease-specific survival following the brachytherapy management of prostate cancer. Int J Radiat Oncol Biol Phys 64 (2006) 810
46. Thompson I.M., Ankerst D.P., Chi C., Goodman P.J., Tangen C.M., Lucia M.S., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529
47. Lynn N.N., Collins G.N., and O'Reilly P.H. The short-term prostate-specific antigen velocity before biopsy can be used to predict prostatic histology. BJU Int 85 (2000) 847
48. Loeb S., Roehl K.A., Catalona W.J., and Nadler R.B. Prostate specific antigen velocity threshold for predicting prostate cancer in young men. J Urol 177 (2007) 899
49. Loberg R.D., Fielhauer J.R., Pienta B.A., Dresden S., Christmas P., Kalikin L.M., et al. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer. Urology 62 suppl. (2003) 128
50. Vollmer R.T., Egawa S., Kuwao S., and Baba S. The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. Cancer 94 (2002) 1692